

Early assessment of the clinical severity of the SARS-CoV-2 in South Africa: a data linkage study

Lancet, The

399, 437-446

DOI: [10.1016/s0140-6736\(22\)00017-4](https://doi.org/10.1016/s0140-6736(22)00017-4)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Mutational and phylogenetic analyses of the two lineages of the Omicron variant. <i>Journal of Medical Virology</i> , 2022, 94, 1777-1779. | 2.5 | 68 |
| 4 | Omicron severity: milder but not mild. <i>Lancet, The</i> , 2022, 399, 412-413. | 6.3 | 124 |
| 5 | Looking at COVID-19 from a Systems Biology Perspective. <i>Biomolecules</i> , 2022, 12, 188. | 1.8 | 1 |
| 7 | Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. <i>Nature Medicine</i> , 2022, 28, 472-476. | 15.2 | 333 |
| 8 | COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research. <i>Blood Reviews</i> , 2022, 54, 100931. | 2.8 | 49 |
| 9 | Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022. <i>Eurosurveillance</i> , 2022, 27, . | 3.9 | 67 |
| 12 | Convulsions in children with COVID-19 during the Omicron wave. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2022, 111, 1023-1026. | 0.7 | 56 |
| 13 | SARS-CoV-2 Variants and Clinical Outcomes: A Systematic Review. <i>Life</i> , 2022, 12, 170. | 1.1 | 39 |
| 17 | Ancestral SARS-CoV-2-specific T cells cross-recognize Omicron. <i>Nature Medicine</i> , 0, , . | 15.2 | 14 |
| 18 | Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding. <i>Viruses</i> , 2022, 14, 295. | 1.5 | 12 |
| 19 | SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. <i>Nature</i> , 2022, 603, 715-720. | 13.7 | 577 |
| 20 | Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. <i>Nature</i> , 2022, 603, 700-705. | 13.7 | 447 |
| 21 | Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. <i>Nature</i> , 2022, 603, 706-714. | 13.7 | 756 |
| 22 | Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. <i>Environmental Research</i> , 2022, 209, 112816. | 3.7 | 189 |
| 24 | Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concern. <i>Journal of Infection</i> , 2022, 84, e80-e81. | 1.7 | 13 |
| 25 | SARS-CoV-2 accessory protein ORF8 is secreted extracellularly as a glycoprotein homodimer. <i>Journal of Biological Chemistry</i> , 2022, 298, 101724. | 1.6 | 28 |
| 26 | SARS-CoV-2 Omicron variant: A next phase of the COVID-19 pandemic and a call to arms for system sciences and precision medicine. <i>MedComm</i> , 2022, 3, e119. | 3.1 | 45 |
| 27 | External validation of the PRIORITY model in predicting COVID-19 critical illness in vaccinated and unvaccinated patients. <i>Clinical Microbiology and Infection</i> , 2022, 28, 884.e1-884.e3. | 2.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 30 | The Omicron subvariant BA.2: Birth of a new challenge during the COVID-19 pandemic. <i>International Journal of Surgery</i> , 2022, 99, 106261. | 1.1 | 45 |
| 31 | Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas. <i>American Journal of Pathology</i> , 2022, 192, 642-652. | 1.9 | 161 |
| 32 | From Free Binding Energy Calculations of SARS-CoV-2 Receptor Interactions to Cellular Immune Responses. <i>Medicina (Lithuania)</i> , 2022, 58, 226. | 0.8 | 6 |
| 35 | Antibody and T-Cell Responses 6 Months after Covid-19 mRNA-1273 Vaccination in Patients with Chronic Kidney Disease, on Dialysis, or Living with a Kidney Transplant. <i>SSRN Electronic Journal</i> , 0, . | 0.4 | 2 |
| 36 | Protective Antibodies and T Cell Responses to Omicron Variant Three Months after the Booster Dose of BNT162b2 Vaccine. <i>SSRN Electronic Journal</i> , 0, . | 0.4 | 0 |
| 37 | More effective vaccines and oral antivirals: Keys for the battle against Omicron. <i>BioScience Trends</i> , 2022, 16, 1-3. | 1.1 | 6 |
| 38 | Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1987. | 1.8 | 48 |
| 39 | Forecast of Omicron Wave Time Evolution. <i>Covid</i> , 2022, 2, 216-229. | 0.7 | 6 |
| 42 | Timing of elective surgery and risk assessment after SARS-CoV-2 infection: an update. <i>Anaesthesia</i> , 2022, 77, 580-587. | 1.8 | 48 |
| 47 | Editorial: Outbreak Investigation: Mental Health in the Times of Coronavirus (COVID-19). <i>Frontiers in Psychiatry</i> , 2022, 13, 854388. | 1.3 | 3 |
| 48 | COVID-19 and children: medical impact and collateral damage. <i>Microbial Biotechnology</i> , 2022, 15, 1035-1049. | 2.0 | 4 |
| 49 | Should asymptomatic patients testing positive for SARS-CoV-2 wait for elective surgical procedures?. <i>British Journal of Anaesthesia</i> , 2022, 128, e311-e314. | 1.5 | 12 |
| 50 | Asymptomatic and pre-symptomatic infection in Coronavirus Disease 2019 pandemic. <i>Medical Review</i> , 2022, 2, 66-88. | 0.3 | 12 |
| 53 | Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. <i>Nature Medicine</i> , 2022, 28, 1063-1071. | 15.2 | 398 |
| 54 | Nonself Mutations in the Spike Protein Suggest an Increase in the Antigenicity and a Decrease in the Virulence of the Omicron Variant of SARS-CoV-2. <i>Covid</i> , 2022, 2, 407-418. | 0.7 | 3 |
| 56 | Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. <i>Medical Microbiology and Immunology</i> , 2022, 211, 79-103. | 2.6 | 9 |
| 57 | Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1. <i>Journal of Virology</i> , 2022, 96, e0024922. | 1.5 | 36 |
| 58 | Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-6. | 1.4 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 59 | Possibility of COVID-19 eradication with evolution of a new omicron variant. <i>Infectious Diseases of Poverty</i> , 2022, 11, 30. | 1.5 | 6 |
| 60 | Molecular SARS-CoV-2 surveillance in Bavaria shows no Omicron transmission before the end of November 2021. <i>Infection</i> , 2022, 50, 761-766. | 2.3 | 2 |
| 61 | Estimation of Serial Interval and Reproduction Number to Quantify the Transmissibility of SARS-CoV-2 Omicron Variant in South Korea. <i>Viruses</i> , 2022, 14, 533. | 1.5 | 57 |
| 62 | The SARS-CoV-2 Omicron (B.1.1.529) variant and the re-emergence of COVID-19 in Europe: An alarm for Bangladesh. <i>Health Science Reports</i> , 2022, 5, e545. | 0.6 | 19 |
| 63 | Effective surveillance of variants. <i>Science</i> , 2022, 375, 1349-1350. | 6.0 | 4 |
| 64 | COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac124. | 0.4 | 25 |
| 65 | SARS-CoV-2 Evolution: On the Sudden Appearance of the Omicron Variant. <i>Journal of Virology</i> , 2022, 96, e0009022. | 1.5 | 32 |
| 66 | COVID-19: preparing for the next viral variant. <i>Medical Journal of Australia</i> , 2022, , . | 0.8 | 0 |
| 67 | SARS-CoV-2 Omicron (B.1.1.529) Variant: Corticosteroids Treatment/Respiratory Coinfection. <i>Frontiers in Immunology</i> , 2022, 13, 856072. | 2.2 | 2 |
| 68 | Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. <i>Science Translational Medicine</i> , 2022, 14, eabn9243. | 5.8 | 84 |
| 70 | Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?. <i>Journal of Virology</i> , 2022, 96, jvi0207721. | 1.5 | 143 |
| 71 | The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921. | 1.8 | 117 |
| 73 | Omicron Variant of SARS-CoV-2 Virus: In Silico Evaluation of the Possible Impact on People Affected by Diabetes Mellitus. <i>Frontiers in Endocrinology</i> , 2022, 13, 847993. | 1.5 | 8 |
| 74 | Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study. <i>Antibiotics</i> , 2022, 11, 345. | 1.5 | 15 |
| 76 | Mutations in the genome of severe acute respiratory syndrome coronavirus 2: implications for COVID-19 severity and progression. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210864. | 0.4 | 5 |
| 77 | mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. <i>Cell</i> , 2022, 185, 1556-1571.e18. | 13.5 | 179 |
| 78 | Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. <i>New England Journal of Medicine</i> , 2022, 386, 1804-1816. | 13.9 | 311 |
| 79 | Association Between Dexamethasone Treatment After Hospital Discharge for Patients With COVID-19 Infection and Rates of Hospital Readmission and Mortality. <i>JAMA Network Open</i> , 2022, 5, e221455. | 2.8 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 81 | Continuous genomic diversification of long polynucleotide fragments drives the emergence of new SARS-CoV-2 variants of concern. , 2022, 1, . | | 4 |
| 83 | Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nature Medicine, 2022, 28, 1042-1049. | 15.2 | 61 |
| 84 | Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models. Journal of Microbiology, 2022, 60, 255-267. | 1.3 | 9 |
| 85 | SARS-CoV-2 Omicron variant: Immune escape and vaccine development. MedComm, 2022, 3, e126. | 3.1 | 74 |
| 86 | Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Cell, 2022, 185, 1539-1548.e5. | 13.5 | 126 |
| 90 | Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments. Annals of Internal Medicine, 2022, 175, 831-837. | 2.0 | 118 |
| 91 | Omicron: fewer adverse outcomes come with new dangers. Lancet, The, 2022, 399, 1280-1281. | 6.3 | 17 |
| 92 | Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet, The, 2022, 399, 1618-1624. | 6.3 | 547 |
| 93 | Smart apps for self-reporting clinical information. Lancet, The, 2022, , . | 6.3 | 1 |
| 94 | SARS-CoV-2 and Liver Transplant: How Has It Behaved in This Sixth Wave?. Transplantation, 2022, 106, 1445-1449. | 0.5 | 5 |
| 95 | Real World Estimate of Vaccination Protection in Individuals Hospitalized for COVID-19. Vaccines, 2022, 10, 550. | 2.1 | 4 |
| 96 | Infections with the SARS-CoV-2 Omicron variant show a similar outcome as infections with the previous variants in patients with hematologic malignancies. Annals of Hematology, 2022, 101, 1877-1878. | 0.8 | 8 |
| 97 | Eigenvalue analysis of SARS-CoV-2 viral load data: illustration for eight COVID-19 patients. International Journal of Data Science and Analytics, 2022, , 1-10. | 2.4 | 2 |
| 98 | Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. Blood Cancer Discovery, 2022, 3, 181-193. | 2.6 | 12 |
| 99 | Omicron "Decoupling" Infection from Severe Disease. New England Journal of Medicine, 2022, 386, 1361-1362. | 13.9 | 7 |
| 101 | Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet, The, 2022, 399, 1303-1312. | 6.3 | 889 |
| 102 | Estimating surge in COVID-19 cases, hospital resources and PPE demand with the interactive and locally-informed COVID-19 Health System Capacity Planning Tool. International Journal of Population Data Science, 2020, 5, 1710. | 0.1 | 1 |
| 103 | Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada. JAMA - Journal of the American Medical Association, 2022, 327, 1286. | 3.8 | 222 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 104 | Infection control strategies for patients and accompanying persons during the COVID-19 pandemic in German hospitals: a cross-sectional study in March–April 2021. <i>Journal of Hospital Infection</i> , 2022, 125, 28-36. | 1.4 | 2 |
| 105 | Omicron™s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals. <i>Science</i> , 2022, 25, 104076. | 1.9 | 25 |
| 107 | Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections – a survival analysis. <i>International Journal of Infectious Diseases</i> , 2022, 118, 150-154. | 1.5 | 22 |
| 108 | Risk stratification and assessment framework for international travel and border measures amidst the COVID-19 pandemic – A Malaysian perspective. <i>Travel Medicine and Infectious Disease</i> , 2022, 47, 102318. | 1.5 | 1 |
| 109 | Decreased severity of the Omicron variant of concern: further evidence from Italy. <i>International Journal of Infectious Diseases</i> , 2022, 119, 21-23. | 1.5 | 8 |
| 110 | A concise review of mushrooms antiviral and immunomodulatory properties that may combat against COVID-19. <i>Journal of Fungi</i> , 2022, 1, 100023. | | 25 |
| 111 | mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. <i>Science Translational Medicine</i> , 2022, 14, eabm2311. | 5.8 | 100 |
| 113 | First-generation BNT162b2 and AZD1222 vaccines protect from COVID-19 pneumonia during the Omicron variant emergence. <i>Public Health</i> , 2022, 207, 105-107. | 1.4 | 7 |
| 115 | Detailed characterization of hospitalized patients infected with the Omicron variant of SARS-CoV-2. <i>Journal of Internal Medicine</i> , 2022, 292, 385-387. | 2.7 | 3 |
| 116 | Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. <i>New England Journal of Medicine</i> , 2022, 386, 1603-1614. | 13.9 | 213 |
| 117 | Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12. | 1.4 | 10 |
| 119 | Identification of SARS-CoV-2 Omicron variant using spike gene target failure and genotyping assays, Gauteng, South Africa, 2021. <i>Journal of Medical Virology</i> , 2022, 94, 3676-3684. | 2.5 | 23 |
| 120 | Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial. <i>Lancet Infectious Diseases</i> , 2022, 22, 990-1001. | 4.6 | 16 |
| 121 | COVID-19 severity from Omicron and Delta SARS-CoV-2 variants. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 832-836. | 1.5 | 60 |
| 122 | Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. <i>Tropical Medicine and International Health</i> , 2022, 27, 564-573. | 1.0 | 94 |
| 123 | Suboptimal Antispikes Antibody Levels Following Vaccination in Recipients of Solid Organ Transplant – Variance of Concern. <i>JAMA Network Open</i> , 2022, 5, e226880. | 2.8 | 1 |
| 126 | Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, e361-e367. | 2.9 | 83 |
| 128 | Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. <i>Journal of Infectious Diseases</i> , 2022, 226, 1593-1607. | 1.9 | 559 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 129 | Structural and functional impact by SARS-CoV-2 Omicron spike mutations. <i>Cell Reports</i> , 2022, 39, 110729. | 2.9 | 102 |
| 130 | SARS-CoV-2 Delta and Omicron Variants Surge in Curitiba, Southern Brazil, and Its Impact on Overall COVID-19 Lethality. <i>Viruses</i> , 2022, 14, 809. | 1.5 | 17 |
| 131 | COVID-19: Omicron “the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2. <i>Microbial Biotechnology</i> , 2022, 15, 1927-1939. | 2.0 | 41 |
| 132 | The displacement of the SARS-CoV-2 variant Delta with Omicron: An investigation of hospital admissions and upper respiratory viral loads. <i>EBioMedicine</i> , 2022, 79, 104008. | 2.7 | 89 |
| 133 | SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa. <i>Emerging Infectious Diseases</i> , 2022, 28, 1055-1058. | 2.0 | 17 |
| 134 | Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 959-966. | 4.6 | 202 |
| 135 | Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 967-976. | 4.6 | 140 |
| 136 | Sustainability of surveillance systems for SARS-CoV-2. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 914-915. | 4.6 | 5 |
| 137 | Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 689-699. | 5.2 | 108 |
| 138 | The immune response to COVID-19: Does sex matter?. <i>Immunology</i> , 2022, 166, 429-443. | 2.0 | 18 |
| 139 | The Emergence of Omicron SARS-CoV-2 Variant (B.1.1.529): The Latest Episode in the COVID-19 Pandemic with a Global Riposte. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, . | 0.4 | 2 |
| 140 | Histoire exceptionnelle d’un article peu banal. <i>Annales Francaises De Medecine D’Urgence</i> , 2022, 12, 73-75. | 0.0 | 1 |
| 141 | Autophagy and evasion of the immune system by SARS-CoV-2. Structural features of the non-structural protein 6 from wild type and Omicron viral strains interacting with a model lipid bilayer. <i>Chemical Science</i> , 2022, 13, 6098-6105. | 3.7 | 11 |
| 142 | Covid-19: virology, variants, and vaccines. , 2022, 1, e000040. | | 24 |
| 143 | Overlapping Delta and Omicron Outbreaks During the COVID-19 Pandemic: Dynamic Panel Data Estimates. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e37377. | 1.2 | 2 |
| 144 | Coronavirus Disease 2019 Vaccination During Pregnancy and Breastfeeding: A Review of Evidence and Current Recommendations in Europe, North America, and Australasia. <i>Frontiers in Pediatrics</i> , 2022, 10, 883953. | 0.9 | 5 |
| 145 | Characterisation of Omicron Variant during COVID-19 Pandemic and the Impact of Vaccination, Transmission Rate, Mortality, and Reinfection in South Africa, Germany, and Brazil. <i>BioTech</i> , 2022, 11, 12. | 1.3 | 23 |
| 146 | Induction of High Neutralizing Activity Against Both Omicron BA.2 and Omicron BA.1 by Coronavirus Disease 2019 Messenger RNA Booster Vaccination. <i>Journal of Infectious Diseases</i> , 2022, 226, 1481-1483. | 1.9 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 147 | Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. <i>Lancet Rheumatology</i> , The, 2022, 4, e417-e429. | 2.2 | 33 |
| 149 | Monoclonal Antibody Therapy in Kidney Transplant Recipients With Delta and Omicron Variants of SARS-CoV-2: A Single-Center Case Series. <i>Kidney Medicine</i> , 2022, 4, 100470. | 1.0 | 11 |
| 150 | Delays in the arrival of the waves of COVID-19: a comparison between Gabon and the African continent. <i>Lancet Microbe</i> , The, 2022, 3, e476. | 3.4 | 2 |
| 151 | SARS-CoV-2 Omicron variant: recent progress and future perspectives. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 141. | 7.1 | 315 |
| 152 | Omicron surge and the future of COVID-19 vaccinations. <i>Medical Journal of Indonesia</i> , 2022, 31, 80-4. | 0.2 | 0 |
| 154 | SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance. <i>Frontiers in Immunology</i> , 2022, 13, 877101. | 2.2 | 74 |
| 155 | SARS-CoV-2 Transmission Control Measures in the Emergency Department: The Role of Rapid Antigenic Testing in Asymptomatic Subjects. <i>Healthcare (Switzerland)</i> , 2022, 10, 790. | 1.0 | 2 |
| 156 | Shell Disorder Models Detect That Omicron Has Harder Shells with Attenuation but Is Not a Descendant of the Wuhan-Hu-1 SARS-CoV-2. <i>Biomolecules</i> , 2022, 12, 631. | 1.8 | 4 |
| 157 | Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, 2161-2168. | 2.9 | 35 |
| 159 | Making a Joint Decision Regarding The Timing of Surgery For Elective Arthroplasty Surgery After Being Infected With COVID-19: A Systematic Review. <i>Journal of Arthroplasty</i> , 2022, , . | 1.5 | 5 |
| 160 | Omicron: A Blessing in Disguise?. <i>Frontiers in Public Health</i> , 2022, 10, 875022. | 1.3 | 2 |
| 161 | SARS-CoV-2 variants " Evolution, spike protein, and vaccines. <i>Biomedical Journal</i> , 2022, 45, 573-579. | 1.4 | 26 |
| 163 | Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study. <i>The Lancet Healthy Longevity</i> , 2022, 3, e347-e355. | 2.0 | 39 |
| 164 | SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022. <i>Eurosurveillance</i> , 2022, 27, . | 3.9 | 28 |
| 165 | Omicron Variant in the Critical Care Units of the Paris Metropolitan Area: The Reality Research Group. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 349-363. | 2.5 | 19 |
| 167 | Emerging SARS-CoV-2 variants: Why, how, and what's next?. , 2022, 1, 100029. | | 26 |
| 168 | Pathogenicity of SARS-CoV-2 Omicron. <i>Clinical and Translational Medicine</i> , 2022, 12, e880. | 1.7 | 12 |
| 169 | Clinical Characteristics of COVID-19 Patients Infected by the Omicron Variant of SARS-CoV-2. <i>Frontiers in Medicine</i> , 2022, 9, . | 1.2 | 39 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 170 | Omicron infection enhances Delta antibody immunity in vaccinated persons. <i>Nature</i> , 2022, 607, 356-359. | 13.7 | 66 |
| 171 | Immuno-Thrombotic Complications of COVID-19: Implications for Timing of Surgery and Anticoagulation. <i>Frontiers in Surgery</i> , 2022, 9, . | 0.6 | 23 |
| 172 | Modeling transmission of SARS-CoV-2 Omicron in China. <i>Nature Medicine</i> , 2022, 28, 1468-1475. | 15.2 | 177 |
| 173 | COVID-19 Variants and Transfer Learning for the Emerging Stringency Indices. <i>Neural Processing Letters</i> , 2023, 55, 2359-2368. | 2.0 | 10 |
| 174 | Immune response in COVID-19: what is next?. <i>Cell Death and Differentiation</i> , 2022, 29, 1107-1122. | 5.0 | 69 |
| 175 | Integrin/TGF- β 1 Inhibitor GLPG-0187 Blocks SARS-CoV-2 Delta and Omicron Pseudovirus Infection of Airway Epithelial Cells In Vitro, Which Could Attenuate Disease Severity. <i>Pharmaceuticals</i> , 2022, 15, 618. | 1.7 | 12 |
| 176 | Is Omicron the end of pandemic or start of a new innings?. <i>Travel Medicine and Infectious Disease</i> , 2022, 48, 102332. | 1.5 | 27 |
| 177 | Proteomic characterization of Omicron SARS-CoV-2 host response. <i>Cell Discovery</i> , 2022, 8, 46. | 3.1 | 8 |
| 178 | Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. <i>Nature</i> , 2022, 607, 351-355. | 13.7 | 143 |
| 179 | MIS-C Triggered by Omicron Variant of SARS-CoV-2.. <i>Indian Pediatrics</i> , 2022, 59, 427-428. | 0.2 | 0 |
| 182 | Decoding the next SARS-CoV-2 variant. <i>The Lancet Global Health</i> , 2022, , . | 2.9 | 0 |
| 183 | SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines. <i>European Journal of Cancer</i> , 2022, 171, 143-149. | 1.3 | 3 |
| 184 | Surgical Triage and Timing for Patients With Coronavirus Disease: A Guidance Statement from The Society of Thoracic Surgeons. <i>Annals of Thoracic Surgery</i> , 2022, 114, 387-393. | 0.7 | 3 |
| 187 | Experimental Infection of Mink with SARS-COV-2 Omicron Variant and Subsequent Clinical Disease. <i>Emerging Infectious Diseases</i> , 2022, 28, . | 2.0 | 11 |
| 188 | Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. <i>The Lancet Global Health</i> , 2022, 10, e961-e969. | 2.9 | 120 |
| 189 | Analyzing and Modeling the Spread of SARS-CoV-2 Omicron Lineages BA.1 and BA.2, France, September 2021â€“February 2022. <i>Emerging Infectious Diseases</i> , 2022, 28, 1355-1365. | 2.0 | 18 |
| 190 | Determinants of Spike Infectivity, Processing and Neutralization in SARS-CoV-2 Omicron Subvariants BA.1 and BA.2. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 191 | Estimation of the Seroprevalence and Infection Fatality Rate of the SARS-CoV-2 Omicron Variant Using Antibody Screening of Danish Blood Donors. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 192 | Omicron Infection Induces Low-Level, Narrow-Range SARS-CoV-2 Neutralizing Activity. SSRN Electronic Journal, 0, , . | 0.4 | 1 |
| 193 | Three-Dose Vaccination-Induced Immune Responses Protect Against SARS-CoV-2 Omicron BA.2. SSRN Electronic Journal, 0, , . | 0.4 | 1 |
| 194 | Peritonsillar abscess caused by <i>Prevotella bivia</i> during home quarantine for coronavirus disease 2019. <i>Medicine (United States)</i> , 2022, 101, e29469. | 0.4 | 0 |
| 198 | Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 4 |
| 199 | Elite Athletes With COVID-19: Time to Let Them Compete? Letter to the Editor. <i>Sports Health</i> , 0, , 194173812210935. | 1.3 | 1 |
| 200 | MIS-C Triggered by Omicron Variant of SARS-CoV-2. <i>Indian Pediatrics</i> , 2022, 59, 427-428. | 0.2 | 0 |
| 201 | COVID-19 outbreak trends in South Africa: A comparison of Omicron (B.1.1.529), Delta (B.1.617.2), and Beta (B.1.351) variants outbreak periods. <i>Journal of Infection and Public Health</i> , 2022, 15, 726-733. | 1.9 | 11 |
| 202 | Therapeutic Trends of Cerebrovascular Disease during the COVID-19 Pandemic and Future Perspectives. <i>Journal of Stroke</i> , 2022, 24, 179-188. | 1.4 | 12 |
| 203 | Leveraging South African <sc>HIV</sc> research to define <sc>SARSâ€CoV</sc>â€2 immunity triggered by sequential variants of concern. <i>Immunological Reviews</i> , 2022, 310, 61-75. | 2.8 | 6 |
| 204 | SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicronâ€™s impact in South African population cohorts. <i>Science Translational Medicine</i> , 2022, 14, . | 5.8 | 36 |
| 206 | Could a Lower Toll-like Receptor (TLR) and NF-ÎB Activation Due to a Changed Charge Distribution in the Spike Protein Be the Reason for the Lower Pathogenicity of Omicron?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5966. | 1.8 | 9 |
| 207 | The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 1524-1536. | 3.0 | 39 |
| 208 | Recent insights into SARSâ€CoVâ€2 omicron variant. <i>Reviews in Medical Virology</i> , 2023, 33, . | 3.9 | 29 |
| 209 | SARS-CoV-2 Omicron variants BA.1 and BA.2 both show similarly reduced disease severity of COVID-19 compared to Delta, Germany, 2021 to 2022. <i>Eurosurveillance</i> , 2022, 27, . | 3.9 | 51 |
| 210 | Evaluation of the Panbio COVID-19 Antigen Rapid Diagnostic Test in Subjects Infected with Omicron Using Different Specimens. <i>Microbiology Spectrum</i> , 2022, 10, . | 1.2 | 17 |
| 211 | Feasibility and safety of reducing duration of quarantine for healthcare personnel with high-risk exposures to coronavirus disease 2019 (COVID-19): From alpha to omicron. <i>Infection Control and Hospital Epidemiology</i> , 0, , 1-3. | 1.0 | 1 |
| 212 | Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. <i>Nature Communications</i> , 2022, 13, . | 5.8 | 188 |
| 213 | The benefits of <sc>COVID</sc>â€19 vaccination programmes for children may not outweigh the risks. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2022, 111, 1843-1845. | 0.7 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 214 | Research Progress of SARS-CoV-2 Omicron Variant. <i>Advances in Microbiology</i> , 2022, 11, 49-60. | 0.0 | 0 |
| 215 | COVID-19 Variants in Critically Ill Patients: A Comparison of the Delta and Omicron Variant Profiles. <i>Infectious Disease Reports</i> , 2022, 14, 492-500. | 1.5 | 19 |
| 217 | Human lungs show limited permissiveness for SARS-CoV-2 due to scarce ACE2 levels but virus-induced expansion of inflammatory macrophages. <i>European Respiratory Journal</i> , 2022, 60, 2102725. | 3.1 | 21 |
| 220 | Comprehensive Humoral and Cellular Immune Responses to SARS-CoV-2 Variants in Diverse Chinese Population. <i>Research</i> , 2022, 2022, . | 2.8 | 5 |
| 221 | SARS-CoV-2: A Master of Immune Evasion. <i>Biomedicines</i> , 2022, 10, 1339. | 1.4 | 24 |
| 222 | Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak. <i>Leukemia and Lymphoma</i> , 2022, 63, 2686-2690. | 0.6 | 5 |
| 223 | Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 12, 100297. | 1.5 | 37 |
| 224 | COVID-19 infection, and reinfection, and vaccine effectiveness against symptomatic infection among health care workers in the setting of omicron variant transmission in New Delhi, India. , 2022, 3, 100023. | | 21 |
| 225 | Acute Hepatitis of Unknown Origin in Children: Early Observations from the 2022 Outbreak. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 522-530. | 0.7 | 19 |
| 226 | Correlation between chest CT severity scores and clinical and biochemical parameters of COVID-19 pneumonia. <i>Clinical Respiratory Journal</i> , 2022, 16, 497-503. | 0.6 | 11 |
| 227 | Clinical Outcomes of Sotrovimab Treatment in 10 High-Risk Patients with Mild COVID-19: A Case Series. <i>American Journal of Case Reports</i> , 0, 23, . | 0.3 | 0 |
| 228 | Development of a Test System to Detect the Omicron Variant of SARS-CoV-2 and the Frequency of Its Detection in Patients. <i>Bulletin of Experimental Biology and Medicine</i> , 0, , . | 0.3 | 0 |
| 229 | Assessing Vaccination Prioritization Strategies for COVID-19 in South Africa Based on Age-Specific Compartment Model. <i>Frontiers in Public Health</i> , 0, 10, . | 1.3 | 12 |
| 230 | Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct. <i>Science Immunology</i> , 2022, 7, . | 5.6 | 89 |
| 231 | Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance. <i>Vaccines</i> , 2022, 10, 938. | 2.1 | 15 |
| 232 | Application of Monoclonal Antibody Drugs in Treatment of COVID-19: a Review. <i>BioNanoScience</i> , 2022, 12, 1436-1454. | 1.5 | 2 |
| 233 | Challenges in Burn Care during the COVID-19 Pandemic—A Scoping Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 3410. | 1.0 | 0 |
| 234 | Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 235 | Concerns on the Effectiveness of Current COVID-19 Vaccines. <i>Frontiers in Microbiology</i> , 0, 13, . | 1.5 | 0 |
| 236 | Molecular aspects of Omicron, vaccine development, and recombinant strain XE: A review. <i>Journal of Medical Virology</i> , 2022, 94, 4628-4643. | 2.5 | 17 |
| 237 | HYGIEIA: HYpothesizing the Genesis of Infectious Diseases and Epidemics through an Integrated Systems Biology Approach. <i>Viruses</i> , 2022, 14, 1373. | 1.5 | 2 |
| 238 | Characteristics and outcomes of vaccinated and nonvaccinated patients hospitalized in a single Italian hub for COVID-19 during the Delta and Omicron waves in Northern Italy. <i>International Journal of Infectious Diseases</i> , 2022, 122, 420-426. | 1.5 | 10 |
| 241 | Reduction in Chest CT Severity and Improved Hospital Outcomes in SARS-CoV-2 Omicron Compared with Delta Variant Infection. <i>Radiology</i> , 2023, 306, 261-269. | 3.6 | 53 |
| 242 | Timing of surgery and elective perioperative management of patients with previous SARS-CoV-2 infection: a SIAARTI expert consensus statement. <i>Journal of Anesthesia, Analgesia and Critical Care</i> , 2022, 2, . | 0.5 | 1 |
| 244 | Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. <i>Nature Medicine</i> , 2022, 28, 1933-1943. | 15.2 | 243 |
| 245 | Clinical Severity of SARS-CoV-2 Omicron Variant Compared with Delta among Hospitalized COVID-19 Patients in Belgium during Autumn and Winter Season 2021â€“2022. <i>Viruses</i> , 2022, 14, 1297. | 1.5 | 41 |
| 246 | University-Associated SARS-CoV-2 Omicron BA.2 Infections, Maricopa County, Arizona, USA, 2022. <i>Emerging Infectious Diseases</i> , 2022, 28, 1520-1522. | 2.0 | 4 |
| 247 | Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022, , . | 1.0 | 0 |
| 249 | SARS-CoV-2 B.1.1.529 (Omicron) Variant Causes an Unprecedented Surge in Children Hospitalizations and Distinct Clinical Presentation Compared to the SARS-CoV-2 B.1.617.2 (Delta) Variant. <i>Frontiers in Pediatrics</i> , 0, 10, . | 0.9 | 14 |
| 251 | Chest CT Findings in Hospitalized Patients with SARS-CoV-2: Delta versus Omicron Variants. <i>Radiology</i> , 2023, 306, 252-260. | 3.6 | 33 |
| 253 | COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periods. <i>Nature Communications</i> , 2022, 13, . | 5.8 | 29 |
| 254 | A Comparison Between Omicron and Earlier COVID-19 Variants' Disease Severity in the Milan Area, Italy. , 0, 2, . | | 8 |
| 255 | Clinical outcomes of the omicron variant compared with previous SARS-CoV-2 variants; meta-analysis of current reports. <i>World Journal of Meta-analysis</i> , 2022, 10, 177-185. | 0.1 | 0 |
| 257 | Percentage of Asymptomatic Infections among SARS-CoV-2 Omicron Variant-Positive Individuals: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 1049. | 2.1 | 64 |
| 258 | Case Report: The Experience of Managing a Moderate ARDS Caused by SARS-CoV-2 Omicron BA.2 Variant in Chongqing, China: Can We Do Better?. <i>Frontiers in Medicine</i> , 0, 9, . | 1.2 | 0 |
| 259 | A Method for Variant Agnostic Detection of SARS-CoV-2, Rapid Monitoring of Circulating Variants, and Early Detection of Emergent Variants Such as Omicron. <i>Journal of Clinical Microbiology</i> , 2022, 60, . | 1.8 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 260 | Remote Monitoring and Holistic Care of Home-Isolated COVID-19 Positive Healthcare Workers Through Digital Technology During the Omicron (B.1.1.529) Wave: A Prospective Cohort Study From India. <i>Frontiers in Public Health</i> , 0, 10, . | 1.3 | 2 |
| 261 | Indications for Hospitalization in Children with SARS-CoV-2 Infection during the Omicron Wave in New York City. <i>Children</i> , 2022, 9, 1043. | 0.6 | 4 |
| 263 | A caseâ€‘case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 1950-1958. | 3.0 | 3 |
| 264 | Clinical severity of omicron lineage BA.2 infection compared with BA.1 infection in South Africa. <i>Lancet, The</i> , 2022, 400, 93-96. | 6.3 | 33 |
| 265 | Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7675. | 1.8 | 9 |
| 266 | Admissions to a large tertiary care hospital and Omicron BA.1 and BA.2 SARS-CoV-2 polymerase chain reaction positivity: primary, contributing, or incidental COVID-19. <i>International Journal of Infectious Diseases</i> , 2022, 122, 665-668. | 1.5 | 16 |
| 267 | Milder disease trajectory among COVID-19 patients hospitalised with the SARS-CoV-2 Omicron variant compared with the Delta variant in Norway. <i>Scandinavian Journal of Public Health</i> , 2022, 50, 676-682. | 1.2 | 9 |
| 268 | Clinical characteristics of the Omicron variant - results from a Nationwide Symptoms Survey in the Faroe Islands. <i>International Journal of Infectious Diseases</i> , 2022, 122, 636-643. | 1.5 | 22 |
| 269 | The Real-World Impact of Vaccination on COVID-19 Cases During Europeâ€™s Fourth Wave. <i>International Journal of Public Health</i> , 0, 67, . | 1.0 | 1 |
| 270 | Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. <i>Clinical Infectious Diseases</i> , 2023, 76, e188-e199. | 2.9 | 24 |
| 272 | Point Prevalence Estimates of Activity-Limiting Long-term Symptoms Among United States Adults â‰¥1 Month After Reported Severe Acute Respiratory Syndrome Coronavirus 2 Infection, 1 November 2021. <i>Journal of Infectious Diseases</i> , 2023, 227, 855-863. | 1.9 | 13 |
| 273 | Clinical and Pulmonary CT Characteristics of Patients Infected With the SARS-CoV-2 Omicron Variant Compared With Those of Patients Infected With the Alpha Viral Strain. <i>Frontiers in Public Health</i> , 0, 10, . | 1.3 | 13 |
| 274 | COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar. <i>Journal of Global Health</i> , 0, 12, . | 1.2 | 48 |
| 275 | Epidemiological analysis of the first 1000 cases of SARSâ€‘CoVâ€‘2 lineage BA.1 (B.1.1.529, Omicron) compared with coâ€‘circulating Delta in Wales, UK. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 986-993. | 1.5 | 13 |
| 276 | COVID-19: Challenges of Viral Variants. <i>Annual Review of Medicine</i> , 2023, 74, 31-53. | 5.0 | 43 |
| 277 | SARS-CoV-2 Antibody Response against Mild-to-Moderate Breakthrough COVID-19 in Home Isolation Setting in Thailand. <i>Vaccines</i> , 2022, 10, 1131. | 2.1 | 3 |
| 278 | Temporal changes in the accessory protein mutations of SARSâ€‘CoVâ€‘2 variants and their predicted structural and functional effects. <i>Journal of Medical Virology</i> , 2022, 94, 5189-5200. | 2.5 | 6 |
| 280 | Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters. <i>Journal of Infectious Diseases</i> , 2023, 227, 1143-1152. | 1.9 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 281 | Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges. <i>Clinical Trials</i> , 2022, 19, 561-572. | 0.7 | 2 |
| 283 | Host-Genome Similarity Characterizes the Adaption of SARS-CoV-2 to Humans. <i>Biomolecules</i> , 2022, 12, 972. | 1.8 | 1 |
| 284 | Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters. <i>Emerging Microbes and Infections</i> , 2022, 11, 1778-1786. | 3.0 | 7 |
| 285 | Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study. <i>The Lancet Healthy Longevity</i> , 2022, 3, e470-e480. | 2.0 | 22 |
| 286 | New SARS-CoV-2 Omicron variant " clinical picture, treatment, prevention (literature review). <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2022, 21, 3228. | 0.4 | 9 |
| 287 | Early report on the severity of COVID-19 in hematologic patients infected with the SARS-CoV-2 omicron variant. <i>European Journal of Haematology</i> , 2022, 109, 364-372. | 1.1 | 13 |
| 288 | A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 8 |
| 290 | The effect of COVID certificates on vaccine uptake, health outcomes, and the economy. <i>Nature Communications</i> , 2022, 13, . | 5.8 | 41 |
| 291 | COVID-19-induced excess mortality in Italy during the Omicron wave.. <i>IJID Regions</i> , 2022, 4, 85-87. | 0.5 | 1 |
| 292 | Nasal Mucosa Exploited by SARS-CoV-2 for Replicating and Shedding during Reinfection. <i>Viruses</i> , 2022, 14, 1608. | 1.5 | 2 |
| 293 | Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. <i>Reviews in Medical Virology</i> , 2022, 32, . | 3.9 | 276 |
| 294 | Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. <i>Journal of Hepatology</i> , 2022, 77, 1161-1197. | 1.8 | 46 |
| 295 | The impact of Omicron on outcomes following infection with SARS-CoV-2 in patients with kidney failure in Scotland. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 197-200. | 1.4 | 2 |
| 296 | Evaluation and Clinical Validation of Guanidine-Based Inactivation Transport Medium for Preservation of SARS-CoV-2. <i>Advances in Pharmacological and Pharmaceutical Sciences</i> , 2022, 2022, 1-9. | 0.7 | 1 |
| 298 | Did Hospitalization Age Decrease in Children in the Omicron (B.1.1.529) Era?. <i>Pediatric Infectious Disease Journal</i> , 0, Publish Ahead of Print, . | 1.1 | 2 |
| 299 | Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2. <i>Cell Host and Microbe</i> , 2022, 30, 1255-1268.e5. | 5.1 | 45 |
| 300 | Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1483-1488. | 0.8 | 3 |
| 301 | Clinical Characteristics of Children With SARS-CoV-2 Infection During the Third Wave of the Pandemic: Single Center Experience. <i>Indian Pediatrics</i> , 2022, 59, 531-534. | 0.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 302 | Dynamics of competing SARS-CoV-2 variants during the Omicron epidemic in England. <i>Nature Communications</i> , 2022, 13, . | 5.8 | 22 |
| 303 | SARS-CoV-2 Intermittent Virulence as a Result of Natural Selection. <i>Covid</i> , 2022, 2, 1089-1101. | 0.7 | 1 |
| 305 | Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022. <i>Vaccines</i> , 2022, 10, 1215. | 2.1 | 11 |
| 308 | COVID-19 Severity and Mortality in Two Pandemic Waves in Poland and Predictors of Poor Outcomes of SARS-CoV-2 Infection in Hospitalized Young Adults. <i>Viruses</i> , 2022, 14, 1700. | 1.5 | 7 |
| 309 | SARS-CoV-2 Omicron Induces Enhanced Mucosal Interferon Response Compared to other Variants of Concern, Associated with Restricted Replication in Human Lung Tissues. <i>Viruses</i> , 2022, 14, 1583. | 1.5 | 13 |
| 310 | Initial observations of Jinhua Qinggan Granules, a Chinese medicine, in the mitigation of hospitalization and mortality in high-risk elderly with COVID-19 infection: A retrospective study in an old age home in Hong Kong. <i>Frontiers in Medicine</i> , 0, 9, . | 1.2 | 5 |
| 311 | Inactivated COVID-19 vaccines: durability of Covaxin/BBV152 induced immunity against variants of concern. <i>Journal of Travel Medicine</i> , 2022, 29, . | 1.4 | 10 |
| 313 | Effects of vaccination, new SARS-CoV-2 variants and reinfections on post-COVID-19 complications. <i>Frontiers in Public Health</i> , 0, 10, . | 1.3 | 5 |
| 314 | Critical policies disparity of the first and second waves of COVID-19 in the United Kingdom. <i>International Journal for Equity in Health</i> , 2022, 21, . | 1.5 | 3 |
| 315 | SARS-CoV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients â€“ a comparative long term post-infection study. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 4 |
| 316 | COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron). <i>ELife</i> , 0, 11, . | 2.8 | 36 |
| 317 | Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 From Adult Index Cases With and Without Human Immunodeficiency Virus in South Africa, 2020â€“2021: A Case-Ascertained, Prospective, Observational Household Transmission Study. <i>Clinical Infectious Diseases</i> , 2023, 76, e71-e81. | 2.9 | 6 |
| 319 | Subâ€“lineages of the SARSâ€“CoVâ€“2 Omicron variants:â€“Characteristics and prevention. <i>MedComm</i> , 2022, 3, . | 3.1 | 15 |
| 320 | Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 4 |
| 321 | Severity of maternal SARS-CoV-2 infection and perinatal outcomes of women admitted to hospital during the omicron variant dominant period using UK Obstetric Surveillance System data: prospective, national cohort study. , 2022, 1, e000190. | | 14 |
| 323 | A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, . | 0.4 | 15 |
| 325 | Identification of Potential ACE2-Derived Peptide Mimetics in SARS-CoV-2 Omicron Variant Therapeutics using Computational Approaches. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 7420-7428. | 2.1 | 4 |
| 326 | Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections. <i>Nature Communications</i> , 2022, 13, . | 5.8 | 87 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 327 | Association between COVID-19 and Sick Leave for Healthcare Workers in a Large Academic Hospital in Southern Italy: An Observational Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 9670. | 1.2 | 3 |
| 328 | Assessing the suitability of long non-coding RNAs as therapeutic targets and biomarkers in SARS-CoV-2 infection. <i>Frontiers in Molecular Biosciences</i> , 0, 9, . | 1.6 | 6 |
| 330 | A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants. <i>ELife</i> , 0, 11, . | 2.8 | 10 |
| 331 | Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom. <i>Clinical Infectious Diseases</i> , 0, , . | 2.9 | 43 |
| 332 | Awareness of SARS-CoV-2 Omicron Variant Infection Among Adults With Recent COVID-19 Seropositivity. <i>JAMA Network Open</i> , 2022, 5, e2227241. | 2.8 | 34 |
| 336 | Real-world effectiveness of Yindan Jiedu granules-based treatment on patients infected with the SARS-CoV-2 Omicron variants BA.2 combined with high-risk factors: A cohort study. <i>Frontiers in Pharmacology</i> , 0, 13, . | 1.6 | 0 |
| 338 | Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. <i>JAMA Network Open</i> , 2022, 5, e2228900. | 2.8 | 42 |
| 339 | Symptom Number and Reduced Preinfection Training Predict Prolonged Return to Training after SARS-CoV-2 in Athletes: AWARE IV. <i>Medicine and Science in Sports and Exercise</i> , 2023, 55, 1-8. | 0.2 | 7 |
| 340 | Editorial Commentary on "Severity of Illness Caused by Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern in Children: A Single-Center Retrospective Cohort Study". <i>Journal of the Pediatric Infectious Diseases Society</i> , 0, , . | 0.6 | 0 |
| 341 | The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineage. <i>Emerging Microbes and Infections</i> , 2022, 11, 2093-2101. | 3.0 | 5 |
| 342 | Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study. <i>BMJ, The</i> , 0, , e070695. | 3.0 | 98 |
| 343 | Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1742-1749. | 0.5 | 26 |
| 344 | Comparison of COVID-19 pneumonia during the SARS-CoV-2 Omicron wave and the previous non-Omicron wave in a single facility. <i>Respiratory Investigation</i> , 2022, 60, 772-778. | 0.9 | 17 |
| 345 | Charlson comorbidity index, neutrophil-to-lymphocyte ratio and undertreatment with renin-angiotensin-aldosterone system inhibitors predict in-hospital mortality of hospitalized COVID-19 patients during the omicron dominant period. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 12 |
| 346 | Delineating the Spread and Prevalence of SARS-CoV-2 Omicron Sublineages (BA.1 to BA.5) and Deltacron Using Wastewater in the Western Cape, South Africa. <i>Journal of Infectious Diseases</i> , 2022, 226, 1418-1427. | 1.9 | 10 |
| 347 | Covid-19: is omicron less lethal than delta?. <i>BMJ, The</i> , 0, , o1806. | 3.0 | 20 |
| 348 | Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave. <i>Emerging Microbes and Infections</i> , 2022, 11, 2045-2054. | 3.0 | 39 |
| 349 | COVID-19 Disease Severity in Persons Infected With Omicron BA.1 and BA.2 Sublineages and Association With Vaccination Status. <i>JAMA Internal Medicine</i> , 2022, 182, 1097. | 2.6 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 350 | Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine. <i>Cell Reports Medicine</i> , 2022, 3, 100716. | 3.3 | 16 |
| 351 | Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, January–March 2022. <i>Emerging Infectious Diseases</i> , 2022, 28, 1856-1858. | 2.0 | 86 |
| 352 | Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study. <i>Lancet Regional Health - Europe</i> , The, 2022, 21, 100479. | 3.0 | 29 |
| 353 | Human coronaviruses: The emergence of SARS-CoV-2 and management of COVID-19. <i>Virus Research</i> , 2022, 319, 198882. | 1.1 | 10 |
| 354 | Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113522. | 2.5 | 56 |
| 355 | Temporal distribution and clinical characteristics of the Alpha, Delta and Omicron SARS-CoV-2 variants of concern in Laikipia, Kenya: institutional and community-based genomic surveillance. <i>Wellcome Open Research</i> , 0, 7, 235. | 0.9 | 2 |
| 356 | Excess Mortality among Physicians and Dentists during COVID-19 in Italy: A Cross-Sectional Study Related to a High-Risk Territory. <i>Healthcare (Switzerland)</i> , 2022, 10, 1684. | 1.0 | 4 |
| 357 | Laboratory markers of severity across three COVID-19 outbreaks in Australia: has Omicron and vaccinations changed disease presentation?. <i>Internal and Emergency Medicine</i> , 2023, 18, 43-52. | 1.0 | 8 |
| 358 | Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico. <i>Frontiers in Public Health</i> , 0, 10, . | 1.3 | 4 |
| 359 | COVID-19 vaccine had a significant positive impact on patients with SARS-COV-2 during the third (Omicron) wave in Saudi Arabia. <i>Journal of Infection and Public Health</i> , 2022, 15, 1169-1174. | 1.9 | 8 |
| 360 | Cystatin C is associated with adverse COVID-19 outcomes in diverse populations. <i>IScience</i> , 2022, 25, 105040. | 1.9 | 2 |
| 361 | Characterizing the third wave of COVID-19. <i>Indian Journal of Medical Research</i> , 2022, Publish Ahead of Print, . | 0.4 | 1 |
| 362 | A child with the Omicron variant coronavirus disease 2019 pneumonia complicated with arrhythmia. <i>Pediatrics International</i> , 2022, 64, . | 0.2 | 1 |
| 363 | Revealing the mystery of persistent smell loss in long COVID patients. <i>International Journal of Biological Sciences</i> , 2022, 18, 4795-4808. | 2.6 | 13 |
| 364 | Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines. <i>International Journal of Biological Sciences</i> , 2022, 18, 4781-4791. | 2.6 | 5 |
| 365 | Characteristics of the SARS-CoV-2 Omicron (B.1.1.529) Variant and Emerging Impact on Global Public Health. <i>BMC Clinical Pathology</i> , 2022, 15, 2632010X2211249. | 0.7 | 14 |
| 366 | SARS-CoV-2 Nasopharyngeal Viral Load in Individuals Infected with BA.2, Compared to Alpha, Gamma, Delta and BA.1 Variants: A Single-Center Comparative Analysis. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 367 | COVID-19 Infection: The Virus and Its Origin, the Variants, the Immune Defense, the Multiorgan Autoimmune Reactions, and the Targeted Treatments. <i>Advances in Infectious Diseases</i> , 2022, 12, 568-631. | 0.0 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 369 | SARS-CoV-2 Omicron variant: viral spread dynamics, disease burden, and vaccine effectiveness. , 2022, 1, . | | 4 |
| 372 | Clinical Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Relative to Delta in British Columbia, Canada: A Retrospective Analysis of Whole-Genome Sequenced Cases. <i>Clinical Infectious Diseases</i> , 2023, 76, e18-e25. | 2.9 | 15 |
| 373 | Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Updated Analysis Involving 22,607 Blood Donors Covering the Period October 2021 to April 2022. <i>Viruses</i> , 2022, 14, 1877. | 1.5 | 4 |
| 374 | Epidemiological and clinical features of SARS-CoV-2 infection in children during the outbreak of Omicron variant in Shanghai, March 7–31, 2022. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 1059-1065. | 1.5 | 16 |
| 375 | Antibody Response against Circulating Omicron Variants 8 Months after the Third Dose of mRNA Vaccine. <i>Vaccines</i> , 2022, 10, 1512. | 2.1 | 3 |
| 376 | Sensor-based surveillance for digitising real-time COVID-19 tracking in the USA (DETECT): a multivariable, population-based, modelling study. <i>The Lancet Digital Health</i> , 2022, 4, e777-e786. | 5.9 | 5 |
| 377 | Impact of improved stroke green channel process on the delay of intravenous thrombolysis in patients with acute cerebral infarction during the COVID-19 pandemic: An observational study. <i>Frontiers in Neurology</i> , 0, 13, . | 1.1 | 0 |
| 378 | Relative Hypercoagulopathy of the SARS-CoV-2 Beta and Delta Variants when Compared to the Less Severe Omicron Variants Is Related to TEG Parameters, the Extent of Fibrin Amyloid Microclots, and the Severity of Clinical Illness. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 858-868. | 1.5 | 26 |
| 379 | Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, . | 4.2 | 37 |
| 380 | Comparison of maternal and neonatal outcomes of COVID-19 before and after SARS-CoV-2 omicron emergence in maternity facilities in Malawi (MATSurvey): data from a national maternal surveillance platform. <i>The Lancet Global Health</i> , 2022, 10, e1623-e1631. | 2.9 | 14 |
| 381 | Neutralizing Immunity Induced Against the Omicron BA.1 and BA.2 Variants in Vaccine Breakthrough Infections. <i>Journal of Infectious Diseases</i> , 2022, 226, 1688-1698. | 1.9 | 1 |
| 382 | COVID-19 vaccinations and rates of infections, hospitalizations, ICU admissions, and deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022. <i>Journal of Medical Virology</i> , 2023, 95, . | 2.5 | 10 |
| 383 | Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1757-1766. | 0.5 | 10 |
| 384 | The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants. <i>Journal of Virology</i> , 2022, 96, . | 1.5 | 6 |
| 385 | Computed Tomographic Imaging Features of COVID-19 Pneumonia Caused by the Delta (B.1.617.2) and Omicron (B.1.1.529) Variant in a German Nested Cohort Pilot Study Group. <i>Tomography</i> , 2022, 8, 2435-2449. | 0.8 | 12 |
| 386 | Post-COVID burden: focus on the short-term condition. , 0, Publish Ahead of Print, . | | 2 |
| 387 | SARS-CoV-2 Variant Delta Potently Suppresses Innate Immune Response and Evades Interferon-Activated Antiviral Responses in Human Colon Epithelial Cells. <i>Microbiology Spectrum</i> , 2022, 10, . | 1.2 | 9 |
| 388 | The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity. <i>Journal of Medical Virology</i> , 2023, 95, . | 2.5 | 71 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 389 | Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2. <i>Cell Reports Medicine</i> , 2022, 3, 100743. | 3.3 | 19 |
| 390 | How Sweden approached the <scp>COVID</scp>â€19 pandemic: Summary and commentary on the National Commission Inquiry. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2023, 112, 19-33. | 0.7 | 26 |
| 391 | Microbiological and Clinical Findings of SARS-CoV-2 Infection after 2 Years of Pandemic: From Lung to Gut Microbiota. <i>Diagnostics</i> , 2022, 12, 2143. | 1.3 | 4 |
| 393 | On the Origins of Omicronâ€™s Unique Spike Gene Insertion. <i>Vaccines</i> , 2022, 10, 1509. | 2.1 | 10 |
| 394 | Comparative performance data for multiplex SARS-CoV-2 serological assays from a large panel of dried blood spot specimens. <i>Heliyon</i> , 2022, 8, e10270. | 1.4 | 5 |
| 395 | Analysis of disease burden in socially disadvantaged areas: Mapping of geographical inequalities in COVID-19 morbidity and mortality using a social disadvantage index in Tennessee. <i>Frontiers in Sustainable Cities</i> , 0, 4, . | 1.2 | 0 |
| 396 | Evolving trend change during the COVID-19 pandemic. <i>Frontiers in Public Health</i> , 0, 10, . | 1.3 | 8 |
| 398 | Predicting the sentiment of South Korean Twitter users toward vaccination after the emergence of COVID-19 Omicron variant using deep learning-based natural language processing. <i>Frontiers in Medicine</i> , 0, 9, . | 1.2 | 2 |
| 399 | Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark. <i>Nature Communications</i> , 2022, 13, . | 5.8 | 91 |
| 400 | A Study on the Nature of SARS-CoV-2 Using the Shell Disorder Models: Reproducibility, Evolution, Spread, and Attenuation. <i>Biomolecules</i> , 2022, 12, 1353. | 1.8 | 2 |
| 401 | Clinical comparison of omicron and delta variants in older COVID-19 patients and the effect of vaccination status. <i>Journal of Health Sciences and Medicine</i> , 2022, 5, 1421-1427. | 0.0 | 1 |
| 402 | Metalloprotease-Dependent S2â€2-Activation Promotes Cellâ€™Cell Fusion and Syncytiation of SARS-CoV-2. <i>Viruses</i> , 2022, 14, 2094. | 1.5 | 6 |
| 403 | Characteristics of hospitalised COVID-19 patients during the first two pandemic waves, Gauteng. <i>Southern African Journal of Infectious Diseases</i> , 2022, 37, . | 0.3 | 0 |
| 404 | In vitro and in vivo differences in neurovirulence between D614G, Delta And Omicron BA.1 SARS-CoV-2 variants. <i>Acta Neuropathologica Communications</i> , 2022, 10, . | 2.4 | 24 |
| 405 | Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study. <i>Infection</i> , 2023, 51, 749-757. | 2.3 | 11 |
| 406 | Localized delivery of nanomedicine and antibodies for combating COVID-19. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1828-1846. | 5.7 | 5 |
| 407 | Validation of reduced S-gene target performance and failure for rapid surveillance of SARS-CoV-2 variants. <i>PLoS ONE</i> , 2022, 17, e0275150. | 1.1 | 11 |
| 408 | Methods for early characterisation of the severity and dynamics of SARS-CoV-2 variants: a population-based time series analysis in South Africa. <i>Lancet Microbe</i> , The, 2022, 3, e753-e761. | 3.4 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 409 | Variant-specific SARS-CoV-2 shedding rates in wastewater. <i>Science of the Total Environment</i> , 2023, 857, 159165. | 3.9 | 19 |
| 410 | Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study. <i>Lancet Respiratory Medicine</i> , 2023, 11, 176-187. | 5.2 | 17 |
| 411 | SARS-CoV-2 and paediatric anaesthesia: similar risk to classic viral upper respiratory tract infection, but still more to learn. <i>Anaesthesia</i> , 2023, 78, 263-264. | 1.8 | 0 |
| 412 | The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance. <i>Science</i> , 2022, 378, . | 6.0 | 64 |
| 413 | An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients. <i>ELife</i> , 0, 11, . | 2.8 | 8 |
| 415 | Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa. <i>Nature Communications</i> , 2022, 13, . | 5.8 | 66 |
| 416 | First report of myocarditis in two patients with COVID-19 Omicron variant: case report. <i>European Heart Journal - Case Reports</i> , 2022, 6, . | 0.3 | 8 |
| 418 | SARS-CoV-2 nasopharyngeal viral load in individuals infected with BA.2, compared to Alpha, Gamma, Delta and BA.1 variants: A single-center comparative analysis. <i>Journal of Clinical Virology</i> , 2022, 157, 105299. | 1.6 | 5 |
| 419 | Incidence and severity of postoperative complications in patients undergoing surgery following COVID-19 infection at a tertiary care center in South India. <i>Anesthesia: Essays and Researches</i> , 2022, 16, 268. | 0.2 | 0 |
| 420 | The Importance of Incorporating At-Home Testing Into SARS-CoV-2 Point Prevalence Estimates: Findings From a US National Cohort, February 2022. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e38196. | 1.2 | 10 |
| 421 | Insight into genomic organization of pathogenic coronaviruses, SARS-CoV-2: Implication for emergence of new variants, laboratory diagnosis and treatment options. <i>Frontiers in Molecular Medicine</i> , 0, 2, . | 0.6 | 0 |
| 422 | The Rescue of the Romanian Health System by the Emergency Departments during the Fourth Wave of COVID-19 Pandemic. <i>Life</i> , 2022, 12, 1547. | 1.1 | 1 |
| 423 | On the evolution of SARS-CoV-2 and the emergence of variants of concern. <i>Trends in Microbiology</i> , 2023, 31, 5-8. | 3.5 | 12 |
| 425 | SARS-CoV-2 – The Role of Natural Immunity: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 6272. | 1.0 | 12 |
| 426 | Optimal epidemic control in equilibrium with imperfect testing and enforcement. <i>Journal of Economic Theory</i> , 2022, 206, 105570. | 0.5 | 1 |
| 427 | COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, . | 2.6 | 77 |
| 429 | Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19. <i>Nature Communications</i> , 2022, 13, . | 5.8 | 33 |
| 430 | Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. <i>BMC Medicine</i> , 2022, 20, . | 2.3 | 51 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 431 | Infection, pathology and interferon treatment of the SARS-CoV-2 Omicron BA.1 variant in juvenile, adult and aged Syrian hamsters. , 2022, 19, 1392-1399. | | 5 |
| 432 | Impaired Fibrinolytic Potential Predicts Oxygen Requirement in COVID-19. <i>Journal of Personalized Medicine</i> , 2022, 12, 1711. | 1.1 | 1 |
| 433 | SARS-CoV-2 variants of concern: a review. <i>Monaldi Archives for Chest Disease</i> , 0, , . | 0.3 | 4 |
| 434 | SARS-CoV-2 Variant-Specific Infectivity and Immune Profiles Are Detectable in a Humanized Lung Mouse Model. <i>Viruses</i> , 2022, 14, 2272. | 1.5 | 3 |
| 435 | Clinical features and outcomes of hospitalized patients with COVID-19 during the Omicron wave in Shanghai, China. <i>Journal of Infection</i> , 2023, 86, e27-e29. | 1.7 | 13 |
| 436 | COVID-19 vaccine hesitancy and confidence in the Philippines and Malaysia: A cross-sectional study of sociodemographic factors and digital health literacy. <i>PLOS Global Public Health</i> , 2022, 2, e0000742. | 0.5 | 9 |
| 437 | Omicron variant of SARS-CoV-2: a review of existing literature. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2023, 44, 73-77. | 0.3 | 0 |
| 438 | Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg, Russia: a test-negative case-control study. <i>Respiratory Research</i> , 2022, 23, . | 1.4 | 13 |
| 439 | Systematic lung ultrasound in Omicron-type vs. wild-type COVID-19. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 24, 59-67. | 0.5 | 2 |
| 440 | The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection. <i>Vaccines</i> , 2022, 10, 1699. | 2.1 | 15 |
| 442 | Assessment of the COVID-19 vaccine market landscape in 2021 relative to challenges in low- and middle-income countries. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, . | 1.4 | 2 |
| 443 | Epidemiological characteristics of Omicron and Delta SARS-CoV-2 variant infection in Santiago, Chile. <i>Frontiers in Public Health</i> , 0, 10, . | 1.3 | 5 |
| 444 | COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 816-832. | 1.5 | 12 |
| 446 | Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. <i>Nature Communications</i> , 2022, 13, . | 5.8 | 51 |
| 447 | Comparison of clinical characteristics between SARS-CoV-2 Omicron variant and Delta variant infections in China. <i>Frontiers in Medicine</i> , 0, 9, . | 1.2 | 10 |
| 448 | The Burden of Omicron Variant in Pakistan: An Updated Review. <i>Covid</i> , 2022, 2, 1460-1476. | 0.7 | 1 |
| 449 | Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England. <i>JAMA Network Open</i> , 2022, 5, e2238354. | 2.8 | 43 |
| 450 | Targeting Natural Plant Metabolites for Hunting SARS-CoV-2 Omicron BA.1 Variant Inhibitors: Extraction, Molecular Docking, Molecular Dynamics, and Physicochemical Properties Study. <i>Current Issues in Molecular Biology</i> , 2022, 44, 5028-5047. | 1.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 451 | Omicron SARS-CoV-2 Spike-1 Protein's Decreased Binding Affinity to β 7nAChR: Implications for Autonomic Dysregulation of the Parasympathetic Nervous System and the Cholinergic Anti-Inflammatory Pathway—An In Silico Analysis. <i>BioMedInformatics</i> , 2022, 2, 553-564. | 1.0 | 2 |
| 452 | Circulating Dynamics of SARS-CoV-2 Variants between April 2021 and February 2022 in Turkey. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-7. | 0.7 | 5 |
| 453 | BNT162b2 against COVID-19 in Brazil using a test-negative design: Study protocol and statistical analysis plan. <i>PLoS ONE</i> , 2022, 17, e0276384. | 1.1 | 1 |
| 454 | COVID-19 increased in Italian children in the autumn and winter 2021–2022 period when Omicron was the dominant variant. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 0, , . | 0.7 | 3 |
| 455 | Machine learning-based scoring system to predict in-hospital outcomes in patients hospitalized with COVID-19. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 617-626. | 0.7 | 6 |
| 456 | Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals. <i>BMC Infectious Diseases</i> , 2022, 22, . | 1.3 | 19 |
| 457 | Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (<sc>STAR SIGN</sc> study): effects of biologics on vaccination efficacy of the third dose of <sc>mRNA</sc> vaccines against SARS-CoV-2. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 103-116. | 1.9 | 6 |
| 458 | COVID-19 in Infants Less than 3 Months: Severe or Not Severe Disease?. <i>Viruses</i> , 2022, 14, 2256. | 1.5 | 10 |
| 459 | Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. <i>Nature</i> , 2022, 612, 540-545. | 13.7 | 60 |
| 460 | Preceding anti-spike IgG levels predicted risk and severity of COVID-19 during the Omicron-dominant wave in Santa Fe city, Argentina. <i>Epidemiology and Infection</i> , 0, , 1-19. | 1.0 | 0 |
| 461 | Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant. <i>Emerging Infectious Diseases</i> , 2022, 28, 2278-2288. | 2.0 | 17 |
| 462 | Identification and differential usage of a host metalloproteinase entry pathway by SARS-CoV-2 Delta and Omicron. <i>IScience</i> , 2022, 25, 105316. | 1.9 | 16 |
| 463 | Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort study. <i>Scientific Reports</i> , 2022, 12, . | 1.6 | 7 |
| 464 | Risk Factors for Severe Coronavirus Disease 2019 Among Human Immunodeficiency Virus-Infected and -Uninfected Individuals in South Africa, April 2020–March 2022: Data From Sentinel Surveillance. <i>Open Forum Infectious Diseases</i> , 2022, 9, . | 0.4 | 3 |
| 465 | Pulling it all together: where do we go from here?. , 2023, , 417-454. | | 0 |
| 466 | Comparative study of clinical features and vaccination status in Omicron and non-Omicron infected patients during the third wave in Mumbai, India. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 6135. | 0.3 | 3 |
| 467 | Evaluating methodological approaches to assess the severity of infection with SARS-CoV-2 variants: scoping review and applications on Belgian COVID-19 data. <i>BMC Infectious Diseases</i> , 2022, 22, . | 1.3 | 5 |
| 468 | Whole-genome sequence analysis reveals the circulation of multiple SARS-CoV-2 variants of concern in Nairobi and neighboring counties, Kenya between March and July 2021. <i>Virology Journal</i> , 2022, 19, . | 1.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 469 | An audit of COVID-19 death reporting in counties Cork and Kerry, Ireland, winter 2021â€“2022. <i>Irish Journal of Medical Science</i> , 2023, 192, 1589-1594. | 0.8 | 1 |
| 470 | Rapid and Accurate On-Site Immunodiagnostics of Highly Contagious Severe Acute Respiratory Syndrome Coronavirus 2 Using Portable Surface-Enhanced Raman Scattering-Lateral Flow Assay Reader. <i>ACS Sensors</i> , 2022, 7, 3470-3480. | 4.0 | 24 |
| 471 | Genome characterization, phylogenomic assessment and spatio-temporal dynamics study of highly mutated BA variants from India. <i>Indian Journal of Medical Microbiology</i> , 2022, , . | 0.3 | 1 |
| 472 | SARS-CoV-2 Variants of Concern and Variations within Their Genome Architecture: Does Nucleotide Distribution and Mutation Rate Alter the Functionality and Evolution of the Virus?. <i>Viruses</i> , 2022, 14, 2499. | 1.5 | 4 |
| 473 | Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence. <i>The Cochrane Library</i> , 2022, 2022, . | 1.5 | 14 |
| 474 | A two-step process for in silico screening to assess the performance of qRTPCR kits against variant strains of SARS-CoV-2. <i>BMC Genomics</i> , 2022, 23, . | 1.2 | 1 |
| 475 | Identification of mutations in SARS-CoV-2 PCR primer regions. <i>Scientific Reports</i> , 2022, 12, . | 1.6 | 9 |
| 477 | SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta. <i>Science Advances</i> , 2022, 8, . | 4.7 | 28 |
| 478 | Challenges and Opportunities for Global Genomic Surveillance Strategies in the COVID-19 Era. <i>Viruses</i> , 2022, 14, 2532. | 1.5 | 11 |
| 479 | Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration. <i>Scientific Reports</i> , 2022, 12, . | 1.6 | 2 |
| 480 | Hepatic dysfunctions in COVID-19 patients infected by the omicron variant of SARS-CoV-2. <i>Frontiers in Public Health</i> , 0, 10, . | 1.3 | 2 |
| 481 | Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa. <i>International Journal of Infectious Diseases</i> , 2023, 127, 63-68. | 1.5 | 32 |
| 482 | COVID-19 and ocular complications: A review of ocular manifestations, diagnostic tools, and prevention strategies. <i>Advances in Ophthalmology Practice and Research</i> , 2023, 3, 33-38. | 0.3 | 5 |
| 483 | Comorbidities prolonged viral shedding of patients infected with SARS-CoV-2 omicron variant in Shanghai: A multi-center, retrospective, observational study. <i>Journal of Infection and Public Health</i> , 2023, 16, 182-189. | 1.9 | 9 |
| 484 | Airport terminal passenger forecast under the impact of COVID-19 outbreaks: A case study from China. <i>Journal of Building Engineering</i> , 2023, 65, 105740. | 1.6 | 2 |
| 485 | Prognosis and sequelae of severe COVID-19 patients after 6 months of hospital discharge: A retrospective cohort study. <i>International Journal of Critical Illness and Injury Science</i> , 2022, 12, 211. | 0.2 | 1 |
| 486 | COVID-19 vaccine hesitancy trends in Ghana: a cross-sectional study exploring the roles of political allegiance, misinformation beliefs, and sociodemographic factors. <i>Pan African Medical Journal</i> , 0, 43, . | 0.3 | 11 |
| 487 | Demographic and Clinical Presentation of Hospitalised Patients with SARS-CoV-2 During the First Omicron Wave. <i>European Medical Journal (Chelmsford, England)</i> , 0, , . | 3.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 488 | The Omicron-transformer: Rise of the subvariants in the age of vaccines. <i>Annals of the Academy of Medicine, Singapore</i> , 2022, 51, 712-729. | 0.2 | 9 |
| 489 | Severity of COVID-19 Associated with SARS-CoV-2 Variants Circulating in the Republic of Korea. , 2022, 15, 2873-2895. | | 16 |
| 490 | Comparison of antibody responses to SARS-CoV-2 variants in Australian children. <i>Nature Communications</i> , 2022, 13, . | 5.8 | 13 |
| 491 | Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 565-573. | 0.5 | 8 |
| 493 | Two Years with COVID-19: The Electronic Frailty Index Identifies High-Risk Patients in the Stockholm GeroCovid Study. <i>Gerontology</i> , 2023, 69, 396-405. | 1.4 | 4 |
| 494 | What is the role of aerosol transmission in SARS-Cov-2 Omicron spread in Shanghai?. <i>BMC Infectious Diseases</i> , 2022, 22, . | 1.3 | 14 |
| 495 | Prediction of Omicron Virus Using Combined Extended Convolutional and Recurrent Neural Networks Technique on CT-Scan Images. <i>Interdisciplinary Perspectives on Infectious Diseases</i> , 2022, 2022, 1-11. | 0.6 | 3 |
| 496 | Impact of immunosuppressive treatment and type of SARS-CoV-2 vaccine on antibody levels after three vaccinations in patients with chronic kidney disease or kidney replacement therapy. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 528-540. | 1.4 | 8 |
| 497 | Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, . | 2.0 | 3 |
| 498 | Investigation of differences in coagulation characteristics between hospitalized patients with SARS-CoV-2 Alpha, Delta, and Omicron variant infection using rotational thromboelastometry (ROTEM): A single-center, retrospective, observational study. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, . | 0.9 | 5 |
| 499 | Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2. <i>Epidemiology and Infection</i> , 2023, 151, . | 1.0 | 3 |
| 500 | The rapid and efficient strategy for SARS-CoV-2 Omicron transmission control: analysis of outbreaks at the city level. <i>Infectious Diseases of Poverty</i> , 2022, 11, . | 1.5 | 8 |
| 501 | Public health impact of UK COVID-19 booster vaccination programs during Omicron predominance. <i>Expert Review of Vaccines</i> , 2023, 22, 90-103. | 2.0 | 7 |
| 502 | Interpretable and Predictive Deep Neural Network Modeling of the SARS-CoV-2 Spike Protein Sequence to Predict COVID-19 Disease Severity. <i>Biology</i> , 2022, 11, 1786. | 1.3 | 4 |
| 503 | Manganese-coordinated mRNA vaccines with enhanced mRNA expression and immunogenicity induce robust immune responses against SARS-CoV-2 variants. <i>Science Advances</i> , 2022, 8, . | 4.7 | 24 |
| 504 | Impaired VEGF-A-Mediated Neurovascular Crosstalk Induced by SARS-CoV-2 Spike Protein: A Potential Hypothesis Explaining Long COVID-19 Symptoms and COVID-19 Vaccine Side Effects?. <i>Microorganisms</i> , 2022, 10, 2452. | 1.6 | 8 |
| 506 | Progress Update on the Epidemiology of COVID-19 Variants and the Assessment Status of Developed Vaccines. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2022, 13, 293-299. | 0.2 | 0 |
| 508 | The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts. <i>International Journal of Infectious Diseases</i> , 2022, , . | 1.5 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 509 | The impact of COVID-19 on the cardiovascular health of emerging adults aged 18-25: findings from a scoping review. , 2022, , . | | 0 |
| 510 | Trends in Cases, Hospitalizations, and Mortality Related to the Omicron BA.4/BA.5 Subvariants in South Africa. <i>Clinical Infectious Diseases</i> , 2023, 76, 1468-1475. | 2.9 | 15 |
| 511 | Impact of combination preventative interventions on hospitalization and death under the pandemic of SARS-CoV-2 Omicron variant in China. <i>Journal of Medical Virology</i> , 2023, 95, . | 2.5 | 5 |
| 512 | Clinical Characteristics and Outcomes of Patients Hospitalized With COVID-19 During the First 4 Waves in Zambia. <i>JAMA Network Open</i> , 2022, 5, e2246152. | 2.8 | 0 |
| 513 | Molecular Pathogenesis of Fibrosis, Thrombosis and Surfactant Dysfunction in the Lungs of Severe COVID-19 Patients. <i>Biomolecules</i> , 2022, 12, 1845. | 1.8 | 5 |
| 514 | Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, . | 7.1 | 7 |
| 515 | Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study. <i>Clinical Infectious Diseases</i> , 2023, 76, 1403-1411. | 2.9 | 52 |
| 516 | The impact of COVID-19 vaccination campaign in Hong Kong SAR China and Singapore. <i>Infectious Disease Modelling</i> , 2023, 8, 101-106. | 1.2 | 5 |
| 517 | Assessing the Efficacy of Early Therapies against SARS-CoV-2 in Hematological Patients: A Real-Life Study from a COVID-19 Referral Centre in Northern Italy. <i>Journal of Clinical Medicine</i> , 2022, 11, 7452. | 1.0 | 1 |
| 518 | Cardiovascular, Pulmonary, and Neuropsychiatric Short- and Long-Term Complications of COVID-19. <i>Cells</i> , 2022, 11, 3882. | 1.8 | 7 |
| 519 | Hematological characteristics of COVID-19 patients with fever infected by the Omicron variant in Shanghai: A retrospective cohort study in China. <i>Journal of Clinical Laboratory Analysis</i> , 2023, 37, . | 0.9 | 6 |
| 520 | Severity of COVID-19 among Hospitalized Patients: Omicron Remains a Severe Threat for Immunocompromised Hosts. <i>Viruses</i> , 2022, 14, 2736. | 1.5 | 10 |
| 521 | Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2022, , . | 0.3 | 3 |
| 522 | Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4+ T cell recognition. <i>Nature Immunology</i> , 2022, 23, 1726-1734. | 7.0 | 11 |
| 523 | Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant. <i>Cell Reports Medicine</i> , 2023, 4, 100910. | 3.3 | 5 |
| 525 | Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Variants on Inpatient Clinical Outcome. <i>Clinical Infectious Diseases</i> , 2023, 76, 1539-1549. | 2.9 | 16 |
| 526 | Complications Following Elective Major Noncardiac Surgery Among Patients With Prior SARS-CoV-2 Infection. <i>JAMA Network Open</i> , 2022, 5, e2247341. | 2.8 | 11 |
| 527 | MRI Assessment of Cerebral Blood Flow in Nonhospitalized Adults Who Self-Isolated Due to COVID-19. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 58, 593-602. | 1.9 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 528 | Association between immunity and viral shedding duration in non-severe SARS-CoV-2 Omicron variant-infected patients. <i>Frontiers in Public Health</i> , 0, 10, . | 1.3 | 1 |
| 529 | Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong. <i>The Lancet Regional Health - Western Pacific</i> , 2023, 32, 100660. | 1.3 | 9 |
| 530 | Fatal cases after Omicron BA.1 and BA.2 infection: Results of an autopsy study. <i>International Journal of Infectious Diseases</i> , 2023, 128, 51-57. | 1.5 | 2 |
| 531 | Effect of Tocilizumab on Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta or Omicron Variants: A Propensity-Matched Analysis in Nimes University Hospital, France. <i>Antibiotics</i> , 2023, 12, 88. | 1.5 | 1 |
| 532 | Omicron-BA.1 Dispersion Rates in Mexico Varied According to the Regional Epidemic Patterns and the Diversity of Local Delta Subvariants. <i>Viruses</i> , 2023, 15, 243. | 1.5 | 5 |
| 533 | Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters. <i>Journal of Virology</i> , 0, , . | 1.5 | 4 |
| 534 | Hematological profile of COVID-19 infected children before and after the spread of the Omicron variant in Istanbul. <i>Asian Pacific Journal of Tropical Medicine</i> , 2022, 15, 551. | 0.4 | 1 |
| 535 | A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies. <i>Viruses</i> , 2023, 15, 167. | 1.5 | 87 |
| 536 | New nickel(II) Schiff base complexes as potential tools against SARS-CoV-2 Omicron target proteins: an <i>in silico</i> approach. <i>New Journal of Chemistry</i> , 2023, 47, 2350-2371. | 1.4 | 4 |
| 537 | Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation. <i>Nature</i> , 2023, 615, 143-150. | 13.7 | 52 |
| 538 | Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors. <i>Viruses</i> , 2023, 15, 175. | 1.5 | 33 |
| 539 | An Integrated Radiologic-Pathologic Understanding of COVID-19 Pneumonia. <i>Radiology</i> , 2023, 306, . | 3.6 | 11 |
| 541 | China's U-turn in its COVID-19 policy. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2023, 42, 101197. | 0.6 | 11 |
| 542 | Mitigation of Socio-Economical Inequalities on the Profile of Healthcare Workers Infected with SARS-CoV-2 upon Vaccination: The Experience of a Brazilian Public Healthcare Institution during the Omicron Wave. <i>Covid</i> , 2023, 3, 65-81. | 0.7 | 0 |
| 543 | Mimicking the Biological Sense of Taste In Vitro Using a Taste Organoids-on-a-Chip System. <i>Advanced Science</i> , 2023, 10, . | 5.6 | 8 |
| 544 | Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa. <i>Nature Communications</i> , 2023, 14, . | 5.8 | 15 |
| 545 | Analysis of SARS-CoV-2 Cases, COVID-19 Outcomes and Vaccinations, during the Different SARS-CoV-2 Variants in Greece. <i>Vaccines</i> , 2023, 11, 126. | 2.1 | 2 |
| 546 | One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. <i>Blood Cancer Journal</i> , 2023, 13, . | 2.8 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 547 | SARS-CoV-2 variants induce distinct disease and impact in the bone marrow and thymus of mice. IScience, 2023, 26, 105972. | 1.9 | 3 |
| 548 | Weekly symptom profiles of nonhospitalized individuals infected with SARS-CoV-2 during the Omicron outbreak in Hong Kong: A retrospective observational study from a telemedicine center. Journal of Medical Virology, 2023, 95, . | 2.5 | 8 |
| 549 | SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nature Reviews Microbiology, 0, , . | 13.6 | 160 |
| 550 | Clinico-Epidemiological Profile of COVID-19 Patients with Omicron Variant Admitted in a Tertiary Care Center, South India. International Journal of General Medicine, 0, Volume 16, 185-191. | 0.8 | 2 |
| 551 | Maternal and perinatal outcomes following pre-Delta, Delta, and Omicron SARS-CoV-2 variants infection among unvaccinated pregnant women in France and Switzerland: a prospective cohort study using the COVI-PREG registry. Lancet Regional Health - Europe, The, 2023, 26, 100569. | 3.0 | 18 |
| 552 | Outcomes of Omicron sub-lineages BA.1.1 and BA.2 infection compared with the sub-lineage BA.1 infection in emergency departments' patients. Clinical Microbiology and Infection, 2023, 29, 551-553. | 2.8 | 0 |
| 553 | T Cell Immune Responses against SARS-CoV-2 in the With Corona Era. Biomedical Science Letters, 2022, 28, 211-222. | 0.0 | 0 |
| 554 | Clinical Severity in Different Waves of SARS-CoV-2 Infection in Sicily: A Model of Smith's Law of Declining Virulence from Real-World Data. Viruses, 2023, 15, 125. | 1.5 | 5 |
| 555 | Could Earlier Availability of Boosters and Pediatric Vaccines Have Reduced Impact of COVID-19?. , 2022, , . | | 1 |
| 556 | Reduction of the risk of severe COVID-19 due to Omicron compared to Delta variant in Italy (November) Tj ETQq1 1 0.784314 rgBT /Qve 1.5 14 | | |
| 557 | Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?. Emerging Microbes and Infections, 2023, 12, . | 3.0 | 7 |
| 558 | COVID-19 mortality attenuated during widespread Omicron transmission, Denmark, 2020 to 2022. Eurosurveillance, 2023, 28, . | 3.9 | 12 |
| 559 | Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies. Frontiers in Immunology, 0, 13, . | 2.2 | 2 |
| 560 | Immunological and metabolic characteristics of the Omicron variants infection. Signal Transduction and Targeted Therapy, 2023, 8, . | 7.1 | 2 |
| 561 | The Relationship between the Transmission of Different SARS-CoV-2 Strains and Air Quality: A Case Study in China. International Journal of Environmental Research and Public Health, 2023, 20, 1943. | 1.2 | 1 |
| 562 | SARS-CoV-2 Vaccination and Clinical Presentation of COVID-19 in Patients Hospitalized during the Delta- and Omicron-Predominant Periods. Journal of Clinical Medicine, 2023, 12, 961. | 1.0 | 1 |
| 563 | Is there a role for RDTs as we live with COVID-19? An assessment of different strategies. BMJ Global Health, 2023, 8, e010690. | 2.0 | 1 |
| 565 | Comparison of COVID-19 Severity in Vaccinated and Unvaccinated Patients during the Delta and Omicron Wave of the Pandemic in a Romanian Tertiary Infectious Diseases Hospital. Healthcare (Switzerland), 2023, 11, 373. | 1.0 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 566 | Remdesivir for the treatment of COVID-19. The Cochrane Library, 2023, 2023, . | 1.5 | 17 |
| 567 | Characterization of a Vesicular Stomatitis Virus-Vectored Recombinant Virus Bearing Spike Protein of SARS-CoV-2 Delta Variant. Microorganisms, 2023, 11, 431. | 1.6 | 1 |
| 568 | A comparison of four epidemic waves of COVID-19 in Malawi; an observational cohort study. BMC Infectious Diseases, 2023, 23, . | 1.3 | 4 |
| 569 | How public health authorities can use pathogen genomics in health protection practice: a consensus-building Delphi study conducted in the United Kingdom. Microbial Genomics, 2023, 9, . | 1.0 | 1 |
| 570 | Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models. Nature Communications, 2023, 14, . | 5.8 | 10 |
| 572 | Variant-Related Differences in Laboratory Biomarkers among Patients Affected with Alpha, Delta and Omicron: A Retrospective Whole Viral Genome Sequencing and Hospital-Setting Cohort Study. Biomedicines, 2023, 11, 1143. | 1.4 | 3 |
| 573 | Clinical outcomes and phylogenetic analysis in reflection with three predominant clades of SARS-CoV-2 variants. European Journal of Clinical Investigation, 2023, 53, . | 1.7 | 12 |
| 574 | Severity of COVID-19-Related Illness in Massachusetts, July 2021 to December 2022. JAMA Network Open, 2023, 6, e238203. | 2.8 | 0 |
| 575 | Syrian hamster convalescence from prototype SARS-CoV-2 confers measurable protection against the attenuated disease caused by the Omicron variant. PLoS Pathogens, 2023, 19, e1011293. | 2.1 | 7 |
| 576 | Projection of healthcare demand in Germany and Switzerland urged by Omicron wave (January-March) Tj ETQq1 1.0.784314 rgBT /Dv 1.5 1 | 1.5 | 1 |
| 577 | Tight junction protein occludin is an internalization factor for SARS-CoV-2 infection and mediates virus cell-to-cell transmission. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, . | 3.3 | 3 |
| 578 | Clinical and upper airway characteristics of 3715 patients with the Omicron variant of SARS-Cov-2 in Changchun, China. Journal of Infection and Public Health, 2023, 16, 422-429. | 1.9 | 11 |
| 579 | Cardiologic Manifestations in Omicron-Type Versus Wild-Type COVID-19: A Systematic Echocardiographic Study. Journal of the American Heart Association, 2023, 12, . | 1.6 | 5 |
| 580 | Early Introduction and Community Transmission of SARS-CoV-2 Omicron Variant, New York, New York, USA. Emerging Infectious Diseases, 2023, 29, 371-380. | 2.0 | 1 |
| 581 | SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report. , 2023, 11, e005957. | | 3 |
| 582 | Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2024, 42, 187-194. | 0.2 | 3 |
| 584 | Clinical Outcomes of Omicron Variant (B.1.1.529) Infection in Children and Adolescents Hospitalized With COVID-19 in Brazil With Observational Data on the Efficacy of the Vaccines in Adolescents. Pediatric Infectious Disease Journal, 2023, 42, 218-225. | 1.1 | 4 |
| 585 | Prolonged SARS-CoV-2 Infection and Intra-Patient Viral Evolution in an Immunodeficient Child. Pediatric Infectious Disease Journal, 2023, 42, 212-217. | 1.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 586 | Cell-autonomous requirement for ACE2 across organs in lethal mouse SARS-CoV-2 infection. <i>PLoS Biology</i> , 2023, 21, e3001989. | 2.6 | 6 |
| 587 | Comparison of COVID-19 Vaccine-Associated Myocarditis and Viral Myocarditis Pathology. <i>Vaccines</i> , 2023, 11, 362. | 2.1 | 1 |
| 588 | Development and validation of a nomogram to predict failure of 14-day negative nucleic acid conversion in adults with non-severe COVID-19 during the Omicron surge: a retrospective multicenter study. <i>Infectious Diseases of Poverty</i> , 2023, 12, . | 1.5 | 4 |
| 589 | Evaluation of COVID-19 vaccines in primary prevention against infections and reduction in severity of illness following the outbreak of SARS-CoV-2 omicron variant in Shanghai. <i>Frontiers in Medicine</i> , 0, 10, . | 1.2 | 3 |
| 590 | Inflammatory Biomarkers Differ among Hospitalized Veterans Infected with Alpha, Delta, and Omicron SARS-CoV-2 Variants. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 2987. | 1.2 | 5 |
| 591 | The risk of mortality and severe illness in patients infected with the omicron variant relative to delta variant of SARS-CoV-2: a systematic review and meta-analysis. <i>Irish Journal of Medical Science</i> , 2023, 192, 2897-2904. | 0.8 | 2 |
| 593 | SARS-CoV-2 BA.2 (Omicron) variant infection in pediatric liver transplanted recipients and cohabitants during 2022 Shanghai outbreak: a prospective cohort. <i>Virology Journal</i> , 2023, 20, . | 1.4 | 2 |
| 594 | Lower T cell response against SARS-CoV-2 variants of concern after mRNA vaccine and risk of breakthrough infections in people with HIV. <i>Aids</i> , 2023, 37, 877-882. | 1.0 | 3 |
| 596 | Severity of SARS-CoV-2 infection in pregnant women and their neonates during the Omicron period compared to the pre-Omicron period: A retrospective cohort study. <i>Journal of Obstetrics and Gynaecology Research</i> , 2023, 49, 1348-1354. | 0.6 | 1 |
| 597 | Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis. <i>Antibiotics</i> , 2023, 12, 393. | 1.5 | 10 |
| 598 | Hospital Outcomes of Community-Acquired SARS-CoV-2 Omicron Variant Infection Compared With Influenza Infection in Switzerland. <i>JAMA Network Open</i> , 2023, 6, e2255599. | 2.8 | 19 |
| 599 | Integrative network pharmacology and in silico analyses identify the anti-omicron SARS-CoV-2 potential of eugenol. <i>Heliyon</i> , 2023, 9, e13853. | 1.4 | 4 |
| 600 | Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants. <i>Metabolites</i> , 2023, 13, 309. | 1.3 | 13 |
| 601 | Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone. <i>Current Issues in Molecular Biology</i> , 2023, 45, 1741-1761. | 1.0 | 2 |
| 604 | Molecular Determinants of the Early Life Immune Response to COVID-19 Infection and Immunization. <i>Vaccines</i> , 2023, 11, 509. | 2.1 | 0 |
| 605 | A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part). <i>Medicine (United Tj ETQq</i> , 1, 0.784314 rgBT (C | 0.4 | 17 |
| 606 | Long-term interplay between COVID-19 and chronic kidney disease. <i>International Urology and Nephrology</i> , 2023, 55, 1977-1984. | 0.6 | 15 |
| 607 | Temporal distribution and clinical characteristics of the Alpha, Delta and Omicron SARS-CoV-2 variants of concern in Laikipia, Kenya: institutional and community-based genomic surveillance. <i>Wellcome Open Research</i> , 0, 7, 235. | 0.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 608 | Monitoring of SARS-CoV-2 Infection in Ragusa Area: Next Generation Sequencing and Serological Analysis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4742. | 1.8 | 1 |
| 610 | The role of immune activation and antigen persistence in acute and long COVID. <i>Journal of Investigative Medicine</i> , 2023, 71, 545-562. | 0.7 | 17 |
| 611 | Kémedoids clustering of hospital admission characteristics to classify severity of influenza virus infection. <i>Influenza and Other Respiratory Viruses</i> , 2023, 17, . | 1.5 | 2 |
| 612 | Impact of Omicron Variant Infection on Assessment of Spike-Specific Immune Responses Using the EUROIMMUN Quan-T-Cell SARS-CoV-2 Assay and Roche Elecsys Anti-SARS-CoV-2-S. <i>Diagnostics</i> , 2023, 13, 1024. | 1.3 | 0 |
| 614 | Vaccine Effectiveness Against Severe Disease and Death for Patients With COVID-19 During the Delta-Dominant and Omicron-Emerging Periods: A K-COVE Study. <i>Journal of Korean Medical Science</i> , 2023, 38, . | 1.1 | 10 |
| 616 | Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5–11 Years of Age, Israel. <i>Emerging Infectious Diseases</i> , 2023, 29, 771-777. | 2.0 | 5 |
| 617 | Development of a Droplet Digital PCR to Monitor SARS-CoV-2 Omicron Variant BA.2 in Wastewater Samples. <i>Microorganisms</i> , 2023, 11, 729. | 1.6 | 2 |
| 618 | Transmission of SARS-CoV-2 Omicron Variant under a Dynamic Clearance Strategy in Shandong, China. <i>Microbiology Spectrum</i> , 2023, 11, . | 1.2 | 2 |
| 620 | Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, . | 1.4 | 17 |
| 621 | Comparative Analysis of Clinical and CT Findings in Patients with SARS-CoV-2 Original Strain, Delta and Omicron Variants. <i>Biomedicines</i> , 2023, 11, 901. | 1.4 | 5 |
| 622 | Research progress in spike mutations of SARS–CoV–2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971. | 5.0 | 7 |
| 623 | Hematological features of patients with type 2 diabetes depending on the variant of SARS-COV-2. <i>Fiziolohichniy Zhurnal (Kiev, Ukraine: 1994)</i> , 2023, 69, 35-42. | 0.1 | 5 |
| 624 | Healthcare workers affected by COVID-19 in a midwife obstetric unit in Johannesburg, South Africa. <i>African Journal of Midwifery and Women's Health</i> , 2023, 17, 1-8. | 0.3 | 0 |
| 625 | The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection. <i>Genome Biology</i> , 2023, 24, . | 3.8 | 10 |
| 626 | Protection from Omicron Infection in Residents of Nursing and Retirement Homes in Ontario, Canada. <i>Journal of the American Medical Directors Association</i> , 2023, 24, 753-758. | 1.2 | 6 |
| 627 | The disease severity of COVID-19 caused by Omicron variants: A brief review. <i>Annals of Clinical Epidemiology</i> , 2023, 5, 31-36. | 0.3 | 2 |
| 628 | Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case–control study. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, . | 1.4 | 6 |
| 629 | Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses. <i>IScience</i> , 2023, 26, 106540. | 1.9 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 630 | Clinical Characteristics of SARS-CoV-2 Omicron Cases in Pune, Maharashtra, India. <i>Cureus</i> , 2023, , . | 0.2 | 0 |
| 631 | Cost of Illness in Patients With COVID-19 Admitted in Three Brazilian Public Hospitals. <i>Value in Health Regional Issues</i> , 2023, 36, 34-43. | 0.5 | 2 |
| 632 | Treating SARS-CoV-2 Omicron variant infection by molnupiravir for pandemic mitigation and living with the virus: a mathematical modeling study. <i>Scientific Reports</i> , 2023, 13, . | 1.6 | 1 |
| 633 | Immunology of COVID-19. , 2024, , 52-71. | | 0 |
| 634 | Standardized Cumulative Metrics of Excess Mortality to Monitor Health System Resilience Throughout COVID-19 and Other Respiratory Virus Resurgences. <i>American Journal of Epidemiology</i> , 2024, 193, 410-414. | 1.6 | 0 |
| 635 | Development and external validation of prediction models for critical outcomes of unvaccinated COVID-19 patients based on demographics, medical conditions and dental status. <i>Heliyon</i> , 2023, 9, e15283. | 1.4 | 0 |
| 636 | An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters. <i>Nature Communications</i> , 2023, 14, . | 5.8 | 11 |
| 638 | A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions. <i>Npj Systems Biology and Applications</i> , 2023, 9, . | 1.4 | 3 |
| 639 | Characteristics and outcomes of COVID-19 patients during the BA.5 omicron wave in Tehran, Iran: a prospective observational study. <i>BMC Infectious Diseases</i> , 2023, 23, . | 1.3 | 1 |
| 640 | Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies. <i>Open Forum Infectious Diseases</i> , 2023, 10, . | 0.4 | 2 |
| 641 | Trends in Severe Outcomes Among Adult and Pediatric Patients Hospitalized With COVID-19 in the Canadian Nosocomial Infection Surveillance Program, March 2020 to May 2022. <i>JAMA Network Open</i> , 2023, 6, e239050. | 2.8 | 8 |
| 642 | Epidemiological Surveillance Reveals the Rise and Establishment of the Omicron SARS-CoV-2 Variant in Brazil. <i>Viruses</i> , 2023, 15, 1017. | 1.5 | 2 |
| 643 | Rapid assembly of SARS-CoV-2 genomes reveals attenuation of the Omicron BA.1 variant through NSP6. <i>Nature Communications</i> , 2023, 14, . | 5.8 | 15 |
| 644 | The characteristics of <sc>SARSâ€CoV</sc> â€2â€positive children in Australian hospitals: a <sc>PREDICT</sc> network study. <i>Medical Journal of Australia</i> , 0, , . | 0.8 | 0 |
| 645 | Age-specific transmission dynamics under suppression control measures during SARS-CoV-2 Omicron BA.2 epidemic. <i>BMC Public Health</i> , 2023, 23, . | 1.2 | 1 |
| 704 | Definitions and Background Issues. , 2023, , 1-23. | | 0 |
| 778 | Omicron: A SARS-CoV-2 Variant. , 0, , . | | 0 |